Abstract
The presence of serum tumor markers, carbohydrate antigen 242 (CA242), carbohydrate antigen 199 (CA199), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), tumor-supplied group of factors (TSGF) and tumor necrosis factor-α (TNF-α), is closely associated with invasion and metastasis of many malignancies. The expression of these markers were measured in serum taken from 37 pancreatic cancer patients prior to treatment. Levels of CA242, CA199, CA125, CEA and TNF-α expression correlated with tumor size, clinical stage, tumor differentiation, lymph node and liver metastasis (P < 0.05). One month after cryosurgery, serum levels of these markers were significantly reduced compared with levels prior to cryosurgery (P < 0.05), whereas there was no significant difference was found between serum levels before and after chemotherapy (P > 0.05). Thus, cryosurgery is more effective than chemotherapy for decreasing CA242, CA199, CA125, CEA, TSGF and TNF-α serum levels in these patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Banfi G, Bravi S, Ardemagni A (2000) Quantitative analysis of CA125 cytosolic contest in patients with pancreatic cancer. Int J Biol Markers 18:284
Carpelan M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54:385–387
Eickhoff A, Martin W, Hartmann D (2006) A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma. Br J Cancer 94:1572–1574
Gage AA, Baust JG (2007) Cryosurgery for tumors. J Am Coll Surg 205:342–356
Giannini E, Borro P, Botta F (2001) Cholestasis is the main determinant of abnormal CA199 levels in patients with pancreatic cancer. Int J Biol Markers 15:126–129
Giraudo E, Primo L, Audero E (1998) Tumor necrosis factor-α regulates expression of vascular endothelial growth factor receptor and of its coreceptor neuropilin-1 human vascular endothelial cells. J Biol Chem 34:22128–22135
Hirata K, Egawa S, Kimura Y, Nobuoka T, Oshima H, Katsuramaki T (2007) Current status of surgery for PC. Dig Surg 24:137–141
Jiang JT, Wu CP, Deng HF (2004) Serum Level of CEA, CA242 and CA199 in pancreatic cancer. World J Gastroenterol 10:1675–1679
Kang CM, Kim JY, Choi GH (2007) The use of adjusted preoperative CA19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 140:31–35
Kovach SJ, Hendrickson RJ, Cappadona CR (2002) Cryoablation of unresectable PC. Surgery 131:463–465
Michalski CW, Weitz J, Buchler MW (2007) Surgery insight: surgical management of PC. Nat Clin Pract Oncol 24:526–535
Mouraviev V, Polascik TJ (2006) Update on cryosurgery for prostate cancer. Curr Opin Urol 16:152–156
Okusaka T, Ishii H, Funakoshi A, Ueno H, Furuse J, Sumii T (2006) A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. Jpn J Clin Oncol 36:557–563
Park BB, Park JO (2007) A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 60:489–494
Schlieman MG, Bold RJ (2003) Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 138:951–956
Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler M (2008) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586–589
Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V (2006) Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable PC. JOP 7:349–360
Xu KC, Niu LZ (2003) Sequential treatment of transarterial chemoembolization (TACE)-percutaneous cryosurgery for unresectable primary liver cancer. World J Gastroenterol 9:2688–2689
Xu KC, Niu LZ (2008) Cryosurgery with combination of 125iodine seed implantation for the treatment of locally advanced PC. J Dig Dis 9:234–237
Xu KC, Niu LZ, He WB (2003) Percutaneous cryosurgery in combination with ethanol injection for unresectable hepatocellular carcinoma. World J Gastroenterol 59:2686–2689
Xu KC, Niu LZ, Hu YZ (2008) A pilot study on combination of cryosurgery and (125)iodine seed implantation for treatment of locally advanced pancreatic cancer. World J Gastroenterol 14:1603–1611
Acknowledgments
We would like to express our appreciation to Xiaopeng Liu, Zhiju Zhao, Chengqian Feng, and Mengtian Liao for processing clinical samples. The authors also thank the assistance of all medical and nursing staff of Fuda Cancer Hospital who cared for the patients in the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhou, G., Niu, L., Chiu, D. et al. Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients. Biotechnol Lett 34, 1235–1241 (2012). https://doi.org/10.1007/s10529-012-0908-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10529-012-0908-5